Zovirax Articles
WELLCOME INTERIMS DRIVEN BY ZOVIRAX
29 March 1993
NEW DATA ON ZIDOVUDINE, ACICLOVIR COTHERAPY
29 March 1993
EIRE POM TO P SWITCH
15 March 1993
ACICLOVIR SHOULD GO OTC, SAYS UK MCA
1 February 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
ZOVIRAX OF LIMITED USE IN CHICKENPOX?
4 January 1993
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
WELLCOME STARTS ZOVIRAX PROGRAM
14 December 1992
WELLCOME PRETAX PROFITS RISE 25%
2 November 1992
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
FIRST EC LAUNCH OF ZOVIRAX
6 July 1992
WELLCOME LOOKING TO OTC ZOVIRAX
29 June 1992
COPROMOTION DEAL FOR ZOVIRAX IN USA
8 June 1992
ASTRA TO FUND CMV TREATMENT STUDY
25 May 1992
EUROPEAN MARKET FOR SELF-MEDICATION
18 May 1992
NEW ZOVIRAX DATA FOR CHICKENPOX
4 May 1992
ZOVIRAX AND SHINGLES
13 April 1992
MORE EXPANSION AT CHILE'S LABS SAVAL
23 March 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
FURTHER WELLCOME SHARE SELL-OFF
9 March 1992
ZOVIRAX ENDORSED FOR CHICKENPOX
9 March 1992
STOCK MARKET COMMENTARY: EUROPE
9 March 1992
"EXCELLENT START" TO 1992 AT WELLCOME
27 January 1992
DRUG FIRMS ARE STOCK MARKET DARLINGS
13 January 1992
STOCK MARKET COMMENTARY: EUROPE
6 January 1992
ZOVIRAX/RETROVIR COMBO FOR AIDS?
6 January 1992
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
